Zobrazeno 1 - 5
of 5
pro vyhledávání: ''
Autor:
Yi‐Long Wu, Li Zhang, Yun Fan, JianYing Zhou, Qing Zhou, Wei Li, ChengPing Hu, GongYan Chen, Xin Zhang, CaiCun Zhou, Thao Dang, Sara Sadowski, Debra A. Kush, Yu Zhou, Ben Li, Tony Mok
Publikováno v:
International Journal of Cancer
In the global KEYNOTE‐042 study (Clinicaltrials.gov, NCT02220894), pembrolizumab significantly improved overall survival (OS) vs chemotherapy in patients with previously untreated programmed death ligand 1 (PD‐L1)‐positive locally advanced/meta
Publikováno v:
International Journal of Cancer
There is increasing interest regarding potential protective effects of low‐dose aspirin against various gastrointestinal cancers. We aimed to quantify the association between use of low‐dose aspirin and risk of gastric/oesophageal cancer using a
Autor:
Erik Vegt, Sushil K Badrising, Olaf Loosveld, Paul Hamberg, Andries M. Bergman, Ad Oostdijk, Nils Wagenaar, Jules L.L.M. Coenen, Marnix G.E.H. Lam, Vincent van der Noort, Hanneke J. M. Zuetenhorst, Aart Beeker, Filiz Celik, John B. A. G. Haanen, Wilbert Zwart, Rebecca D Louhanepessy
Publikováno v:
International Journal of Cancer
International Journal of Cancer, 147, 4, pp. 1143-51
International Journal of Cancer, 147, 1143-51
International Journal of Cancer, 147, 4, pp. 1143-51
International Journal of Cancer, 147, 1143-51
The ALSYMPCA study established a 3.6 month Overall Survival (OS) benefit in metastatic Castration Resistant Prostate Cancer (mCRPC) patients treated with Radium‐223 dichloride (Ra‐223) over placebo. Here we report clinical outcomes of Ra‐223 tr
Autor:
Jing Chen, Qing Yi, Huiyao Gu, Wen Cao, Li Yang, Jingsong He, Qingxiao Chen, Haimeng Yan, Zhen Cai, Ning Lv, Xi Huang, Enfan Zhang
Publikováno v:
International Journal of Cancer
E3 ubiquitin ligases primarily determine the substrate specificity of the ubiquitin‐proteasome system and play an essential role in the resistance to bortezomib in multiple myeloma (MM). Neural precursor cell‐expressed developmentally downregulat
Autor:
Claudia Quiering, Frederik Marmé, Christian M. Kurbacher, Florin-Andrei Taran, Christoph Mundhenke, J Kreuzeder, Thomas Decker, Wolfgang Janni, Oliver J. Stoetzer, Hans Tesch, Andrea Distelrath, Michael P. Lux, Diana Lüftner, Andreas Schneeweiss, Mathias Muth, Peter A. Fasching, Peyman Hadji
Publikováno v:
International Journal of Cancer
In BOLERO‐2, adding everolimus to exemestane resulted in a twofold increase in median progression‐free survival (PFS) vs exemestane in postmenopausal women with hormone receptor‐positive (HR+), human epidermal growth factor receptor 2‐negativ